Chondropenia followed by epidemic of osteoarthritis: from joint aging to the clinical manifestations
Abstract
Osteoarthritis (OA) is the most wide-spread and socially significant disease of musculoskeletal system. Systemic inflammation and formation of proinflammatory cytokines underlie OA, which, in its turn, conditions keeping pain syndrome and cartilage degradation. Currently, theory of chondropenia, due to age-related reduction of glycosaminoglycans, is actively developed. Modern complex OA therapy should include glycosaminoglycans.
About the Authors
A. V. Naumov
ФГБОУ ВО РНИМУ им. Н. И. Пирогова МЗ РФ
Россия
Россия
N. O. Hovasova
ФГБОУ ВО РНИМУ им. Н. И. Пирогова МЗ РФ
Россия
Россия
O. N. Tkacheva
ФГБОУ ВО РНИМУ им. Н. И. Пирогова МЗ РФ
Россия
Россия
References
1. White A. G., Birnbaum H. G., Janagap C. et al. Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the United States // J Occup Environ Med. 2008. Vol. 50. P. 998–1005.
2. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 // Lancet. 2015, Aug 22; 386 (9995): 743–800.
3. Qin J., Barbour K. E., Murphy L. B. et al. Lifetime risk of symptomatic hand osteoarthritis / The Johnston County Osteoarthritis Project. Arthritis Rheumatol. 2017.
4. Castell M. V., van der Pas S., Otero A. et al. Osteoarthritis and frailty in elderly individuals across six European countries: results from the European Project on OSteoArthritis (EPOSA) // BMC Musculoskeletal Disorders. 2015; 16: 359.
5. Наумов А. В., Шамуилова М. М. Остеоартрит — стратегия решений: взгляд с высоты современных знаний // Consilium Medicum. 2012; 2: 81–85.
6. Breivik H., Collett B., Ventafridda V. et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment // Eur. J. Pain. 2006. Vol. 10. P. 287–333.
7. Наумов А. В., Семенов П. А. Боль в России: факты и умозаключения // Consilium Medicum. 2010; 02: 42–48.
8. Hana S., Aicha B. T., Selim D., Ines M., Rawdha T. Clinical and Radiographic Features of Knee Osteoarthritis of Elderly Patients // Current Rheumatology Reviews. 2018; 14: 181.
9. Cheng K. H., Chu C. S., Lee K. T., Yang Y. H., Tsai W. C., Tang W. H., Sheu S. H., Lai W. T. Osteoarthritis is an independent risk factor for major adverse cardiovascular events-nationwide case-control studies // European Heart Journal. 2013, 1 August, Vol. 34, Issue suppl. 1, p. 5173.
10. Backman C. L. Arthritis and pain. Psychosocial aspects in the management of arthritis pain // Arthritis Res Ther. 2006; 8: 221.
11. Bergman S. Management of musculoskeletal pain // Best Pract Res Clin Rheumatol. 2007; 21: 153–66.
12. Gatchel R. J., Peng Y. B., Peters M. L. et al. The biopsychosocial approach to chronic pain: scientific advances and future directions // Psychol Bull. 2007; 133: 581–624.
13. Mork P. J., Vik K. L., Moe B. et al. Sleep problems, exercise and obesity and risk of chronic musculoskeletal pain: the Norwegian HUNT study // Eur J Public Health. 2014; 24: 924–929.
14. Da Silva J. A. P., Geenen R., Jacobs J. W. G. Chronic widespread pain and increased mortality: biopsychosocial interconnections // Ann Rheum Dis. 2017: annrheumdis-2017, 211893.
15. Pickering M. E., Chapurlat R., Kocher L. et al. Sleep Disturbances and Osteoarthritis // Pain Pract. 2016; 16: 237–244.
16. Speziali A., Delcogliano M., Tei M. et al. Chondropenia: current concept review // Musculoskelet Surg. 2015, 99: 189.
17. Кашеварова Н. Г., Алексеева Л. И., Таскина Е. А., Смирнов А. В. Ведущие факторы прогрессирования остеоартрита коленных суставов. Влияние симптоматических препаратов замедленного деи?ствия на течение заболевания (5-летнее проспективное исследование) // Фарматека. 2017; 7 (340): 40–45.
18. Jiang L., Tian W., Wang Y. et al. Body mass index and susceptibility to knee osteoarthritis: a systematic review and meta-analysi // Joint Bone Spine. 2012, May; 79 (3): 291–297. DOI: 10.1016/j. jbspin.2011.05.015.
19. Homicz M. R., McGowan K. B., Lottman L. M., Beh G., Sah R. L., Watson D. A. Compositional Analysis of Human Nasal Septal Cartilage // Arch Facial Plast Surg. 2003; 5 (1): 53–58.
20. Danesch U., Seybold M., Rittinghausen R., Triebel W., Bitterlich N. NEM® brand eggshell membrane effective in the treatment of pain associated with knee and hip osteoarthritis: results from a six center, open label German clinical study // J Arthritis. 2014; 3: 1000136–41.
21. Brunello E., Masini A. NEM® brand eggshell membrane effective in the treatment of pain and stiffness associated with osteoarthritis of the knee in an Italian study population // Int J Clin Med. 2016; 7: 169–175.
22. Benson K. F., Ruff K. J., Jensen G. S. Effects of Natural Eggshell Membrane (NEM) on Cytokine Production in Cultures of Peripheral Blood Mononuclear Cells: Increased Suppression of Tumor Necrosis Factor-? Levels After In Vitro Digestion // Journal of Medicinal Food. 2012, Apr.
23. Ruff K. J., Winkler A., Jackson R. W., DeVore D. P., Ritz B. W. Eggshell membrane in the treatment of pain and stiffness from osteoarthritis of the knee: a randomized, multicenter, double-blind, placebo-controlled clinical study // Clinical Rheumatology. 2009; 28 (8): 907–914.
24. Ruff K. J., DeVore D. P., Leu M. D., Robinson M. A. Eggshell membrane: A possible new natural therapeutic for joint and connective tissue disorders. Results from two open-label human clinical studies // Clinical Interventions in Aging. 2009; 4: 235–240.
Review
For citations:
Naumov A.V., Hovasova N.O., Tkacheva O.N. Chondropenia followed by epidemic of osteoarthritis: from joint aging to the clinical manifestations. Lechaschi Vrach. 2018;(12):69. (In Russ.)
Views:
184
JATS XML
Email this article 
